MA-NETSCOUT-SYSTEMS
22.3.2022 11:02:06 CET | Business Wire | Press release
NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report . During the second half of 2021, cybercriminals launched approximately 4.4 million Distributed Denial of Service (DDoS) attacks, bringing the total number of DDoS attacks in 2021 to 9.75 million. These attacks represent a 3% decrease from the record number set during the height of the pandemic but continue at a pace that's 14% above pre-pandemic levels.
The report details how the second half of 2021 established high-powered botnet armies and rebalanced the scales between volumetric and direct-path (non-spoofed) attacks, creating more sophisticated operating procedures for attackers and adding new tactics, techniques, and methods to their arsenals.
“While it may be tempting to look at the decrease in overall attacks as threat actors scaling back their efforts, we saw significantly higher activity compared to pre-pandemic levels,” said Richard Hummel, threat intelligence lead, NETSCOUT. “The reality is that attackers are constantly innovating and adapting new techniques, including the use of server-class botnets, DDoS-for-Hire services, and increased used direct-path attacks that continually perpetuate the advancement of the threat landscape.”
Other key findings from the NETSCOUT 2H2021 Threat Intelligence Report include:
- DDoS Extortion and Ransomware Operations are on the rise. Three high-profile DDoS extortion campaigns simultaneously operating is a new high. Ransomware gangs including Avaddon, REvil, BlackCat, AvosLocker, and Suncrypt were observed using DDoS to extort victims. Because of their success, ransomware groups have DDoS extortion operators masquerading as affiliates like the recent REvil DDoS Extortion campaign.
- VOIP Services were Targets of DDoS Extortion. Worldwide DDoS extortion attack campaigns from the REvil copycat were waged against several VOIP services providers. One VOIP service provider reported $9M-$12M in revenue loss due to DDoS attacks.
- DDoS-for-Hire services made attacks easy to launch. NETSCOUT examined 19 DDoS-for-Hire services and their capabilities that eliminate the technical requirements and cost of launching massive DDoS attacks. When combined, they offer more than 200 different attack types.
- APAC attacks increased by 7% as other regions subsided . Amid ongoing geopolitical tensions in China, Hong Kong, and Taiwan, the Asia-Pacific region saw the most significant increase in attacks year over year compared to other regions.
- Server-class botnet armies arrived. Cybercriminals have not only increased the number of Internet-of-Things (IoT) botnets but have also conscripted high-powered servers and high-capacity network devices, as seen with the GitMirai, Meris, and Dvinis botnets.
- Direct-path attacks are gaining in popularity . Adversaries inundated organizations with TCP- and UDP-based floods, otherwise known as direct-path or non-spoofed attacks. Meanwhile, a decrease in some amplification attacks drove down the number of total attacks.
- Attackers targeted select industries . Those hardest hit include software publishers (606% increase), insurance agencies and brokers (257% increase), computer manufacturers (162% increase), and colleges, universities, and professional schools (102% increase)
- The fastest DDoS attack recorded a 107% year-over-year increase. Using DNS, DNS amplification, ICMP, TCP, ACK, TCP RST, and TCP SYN vectors, the multi-vector attack against a target in Russia recorded 453 Mpps.
NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data captured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with insights from NETSCOUT's ATLAS Security Engineering & Response Team.
The visibility and insights compiled from the global DDOS attack data, which is represented in the Threat Intelligence Report and can be seen in the Omnis Threat Horizon portal, fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security portfolio to detect and block threat activity for enterprises and service providers worldwide.
Visit our interactive website for more information on NETSCOUT's semi-annual Threat Intelligence Report. You can also find us on Facebook , LinkedIn , and Twitter for threat updates and the latest trends and insights.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Omnis® Cyber Intelligence delivers the fastest and most scalable network security solution available on the market. NETSCOUT nGenius® service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor® Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.
©2022 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005111/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
